The global Chronic Kidney Disease Diagnostics Market has experienced substantial growth over the past decade, driven by rising prevalence of kidney disorders, aging populations, and increasing awareness of early detection. Valued at USD 6.1 billion in 2022, the market is projected to reach USD 12.8 billion by 2032, expanding at a CAGR of 7.6% from 2023 to 2032. According to WHO data, over 850 million people worldwide are affected by kidney diseases, with chronic kidney disease (CKD) accounting for nearly 10% of the global adult population.

Between 2015 and 2022, the market grew from USD 4.2 billion to USD 6.1 billion, reflecting an average annual growth rate of 6.4%. The increasing incidence of diabetes and hypertension, major contributors to CKD, has further accelerated demand for diagnostic solutions such as serum creatinine testing, urine albumin tests, and imaging techniques.

Market Overview and Historical Trends

In 2015, the CKD diagnostics market was valued at USD 4.2 billion and rose to USD 4.8 billion in 2016, registering a year-over-year growth of 14.3%. From 2017 to 2019, the market witnessed moderate expansion, reaching USD 5.4 billion in 2017 and USD 5.9 billion in 2019. Despite the COVID-19 pandemic in 2020, the market only slightly dipped to USD 5.8 billion due to delayed elective testing, before rebounding to USD 6.0 billion in 2021. By 2022, the market surged to USD 6.1 billion, indicating a recovery growth rate of 3.3% year-over-year.

Over the past seven years, North America consistently dominated the market, accounting for 38% of global revenue in 2022. The U.S. alone contributed USD 2.3 billion in 2022, up from USD 1.5 billion in 2015, reflecting a CAGR of 6.5%. Europe ranked second with a market size of USD 1.8 billion in 2022, growing at a CAGR of 5.9% since 2015. Asia-Pacific emerged as the fastest-growing region, with revenue increasing from USD 0.8 billion in 2015 to USD 1.3 billion in 2022, registering a CAGR of 7.3%.

Key Market Drivers

The increasing prevalence of diabetes and hypertension remains the primary driver of the chronic kidney disease diagnostics market. The International Diabetes Federation reported that 537 million adults had diabetes globally in 2021, with nearly 40% at risk of CKD. Hypertension prevalence exceeded 1.2 billion adults worldwide in 2020, further driving diagnostic demand.

Government initiatives and funding have played a critical role. The U.S. National Kidney Foundation allocated USD 175 million for CKD screening programs in 2021, up from USD 150 million in 2018. Similarly, the European Commission invested EUR 85 million in CKD awareness campaigns and early diagnostic research in 2022. In India, government healthcare programs targeting CKD screening expanded testing facilities from 250 in 2018 to 430 in 2022.

Market Segmentation

By Diagnostic Type

Serum creatinine testing accounted for the largest share of 42% in 2022, generating USD 2.56 billion in revenue globally. Urine albumin and protein tests contributed USD 1.9 billion, or 31%, while imaging techniques such as ultrasound and CT scans accounted for USD 1.2 billion, or 20%. Emerging molecular diagnostics and biomarker testing held a smaller but growing 7% share, valued at USD 0.42 billion in 2022, and is expected to grow at a CAGR of 9.2% through 2032.

By End-User

Hospitals dominated the end-user segment with 55% of market revenue in 2022, totaling USD 3.35 billion. Diagnostic laboratories contributed 32% or USD 1.95 billion, while outpatient clinics and research institutions together accounted for 13%, valued at USD 0.8 billion. Hospital-based testing continues to grow due to integrated patient care and increasing CKD referrals from primary care providers.

Future Projections

The chronic kidney disease diagnostics market is projected to reach USD 12.8 billion by 2032. Serum creatinine and urine albumin testing will remain dominant, collectively contributing over USD 8.5 billion by 2032. Hospitals will continue to lead end-user adoption, with anticipated revenue of USD 7.1 billion in 2032, representing 55% of the total market. Asia-Pacific is forecasted to become the second-largest regional market by 2032, with revenue rising to USD 3.1 billion, driven by rising CKD awareness and increasing healthcare expenditure.

Between 2023 and 2032, the market is expected to register a consistent CAGR of 7.6%, with high growth anticipated in emerging economies. Latin America’s market value will increase from USD 0.5 billion in 2023 to USD 1.0 billion by 2032 at a CAGR of 7.8%. The Middle East & Africa is projected to grow from USD 0.3 billion in 2023 to USD 0.7 billion by 2032, reflecting a CAGR of 8.2%.

Industry Insights

Leading companies such as Abbott Laboratories, Roche Diagnostics, Siemens Healthineers, and Danaher Corporation collectively held over 45% of the market share in 2022. Abbott generated USD 1.1 billion in CKD diagnostic revenue, up from USD 0.78 billion in 2018, representing a 7.3% CAGR. Roche Diagnostics recorded USD 0.95 billion in revenue, a 6.8% CAGR since 2017. Siemens Healthineers achieved USD 0.72 billion in 2022, growing from USD 0.48 billion in 2016, at a CAGR of 6.6%.

Mergers, acquisitions, and strategic partnerships have further strengthened market consolidation. For example, Danaher’s acquisition of Cepheid in 2016 expanded molecular diagnostics offerings, contributing USD 0.38 billion to CKD diagnostics revenue by 2022.

Survey and Production Statistics

A 2022 global survey of 3,500 nephrologists indicated that 76% recommended serum creatinine testing as the first-line CKD diagnostic, while 62% emphasized urine albumin assessment for early-stage detection. Laboratory testing volumes have increased steadily, with an estimated 310 million CKD diagnostic tests conducted globally in 2022, up from 220 million in 2017.

Production volumes for diagnostic kits have also expanded. Abbott produced 45 million CKD testing kits in 2022 compared to 28 million in 2015, reflecting a CAGR of 6.7%. Roche’s production increased from 24 million kits in 2016 to 42 million in 2022.

Conclusion

The chronic kidney disease diagnostics market is poised for robust growth, from USD 6.1 billion in 2022 to USD 12.8 billion by 2032, at a CAGR of 7.6%. Rising prevalence of diabetes and hypertension, growing government initiatives, and technological advancements in molecular and biomarker diagnostics are driving market expansion. North America remains dominant, while Asia-Pacific and Latin America are key emerging markets. Hospitals will continue to lead adoption, and molecular diagnostics are projected to grow fastest at 9.2% CAGR. The industry is highly competitive, with leading players consolidating through strategic acquisitions and expanding production capacities.

Read Full Research Study: https://marketintelo.com/report/chronic-kidney-disease-diagnostics-market